Loading...
Market
Regulatory approval for Asahi Kasei-Calliditas deal by mid-2024?
5
Asahi Kasei•Swedish•Calliditas Therapeutics•American Depositary Share•ADS•Calliditas•Tarpeyo•SofinnovaVC•Amolyt Pharma•CLI LimFlow
Resolution / Starting Odds
Yes • 50%
No • 50%
Public announcements from regulatory agencies or official press releases
Story
Asahi Kasei to Acquire Calliditas Therapeutics for $1.1 Billion in SEK 416 per ADS Deal
May 28, 2024, 09:19 AM
Japanese conglomerate Asahi Kasei has announced its intention to acquire Swedish drugmaker Calliditas Therapeutics for approximately $1.1 billion. The deal, which includes an offer of SEK 416 or about USD $39.37 in cash per American Depositary Share (ADS), aims to bolster Asahi Kasei's pharmaceutical business. Calliditas, known for its IgA nephropathy therapy Tarpeyo, will be acquired for $1.05 billion in cash. The acquisition price is also noted as SEK 208 per share or 1.2 billion dollars. This acquisition marks the third successful exit for SofinnovaVC in the last six months, following the exits of Amolyt Pharma and CLI LimFlow.
View original story
Similar markets
Highly successful integration • 25%
Moderately successful integration • 25%
Integration with issues • 25%
Integration fails • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved without conditions • 33%
Approved with conditions • 33%
Not approved • 33%